Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has awarded a tentative approval to Perrigo's Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Emulsion Foam, 0.05% to treat moderate to severe dermatosis of the scalp.
Subscribe to our email newsletter
Stiefel Research Australia has filed a patent infringement suit in the US District Court for the District of Delaware against Perrigo to stop marketing its Emulsion Foam.
The patent infringement suit was filed because Perrigo’s Clobetasol was similar to Stiefel Laboratories’ topical corticosteroid – Olux -E Foam, 0.05%.
Perrigo manufactures OTC pharmaceutical products and infant formulas and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API).